The transmembrane domains of the EBV-encoded latent membrane protein 1 (LMP1) variant CAO regulate enhanced signalling activity

Virology

Volumn 282, Issue 2, 2001, Pages 278-287

  Blake, Sarah M S ^a   Eliopoulos, Aristides G ^a   Dawson, Christopher W ^a   Young, Lawrence S ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

AP 1; CAO; LMP1; NF B

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LATENT MEMBRANE PROTEIN 1; PROTEIN CAO LMP 1; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG;

ARTICLE; CHIMERA; CONTROLLED STUDY; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; KERATINOCYTE; NASOPHARYNX CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN VARIANT; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

HUMAN HERPESVIRUS 4;

EID: 0035836377     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.2001.0828     Document Type: Article

References (64)

1. Degradation of Epstein-Barr virus latent membrane protein 1 (LMP1) by the ubiquitin-proteasome pathway targetting via ubiquitination of the N-terminal residue
2. DNA sequence and expression of the B95.8 Epstein-Barr virus genome
3. Posttranslational processing of an Epstein-Barr virus-encoded membrane protein expressed in cells transformed by Epstein-Barr virus
4. Carboxy terminal variants of Epstein-Barr virus-encoded latent membrane protein 1 during long-term human immunodeficiency virus infection: Reliable markers for individual strain identification
5. Localization of the major NF-kB-activating site the sole TRAF3 binding site of LMP1 defines two distinct signaling motifs
6. Cloning and characterization of the latent membrane protein (LMP) of a specific Epstein-Barr virus variant derived from the nasopharyngeal carcinoma in the Taiwanese population
7. Specific latent membrane protein 1 gene sequences in type 1 and type 2 Epstein-Barr virus from nasopharyngeal carcinoma in Hong Kong
8. Prevalence of LMP1 deletion variant of Epstein-Barr virus in nasopharyngeal carcinoma and gastric tumours in Hong Kong
9. Comparative analysis of Epstein-Barr virus gene polymorphisms in nasal T/NK-cell lymphomas and normal nasal tissues: Implications on virus strain selection in malignancy
10. Identification of functional differences between prototype Epstein-Barr virus-encoded LMP1 and a nasopharyngeal carcinoma-derived LMP1 in human epithelial cells
11. Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation
12. Association of TRAF1, TRAF2 and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-Lymphocyte transformation: Role in NF-κB activation
13. Epstein-Barr virus-encoded latent membrane protein 1 activates the JNK pathway via a mechanism involving TRADD and TRAF2
14. CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr virus-encoded LMP1: Involvement of TRAF3 as a common mediator
15. Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production
16. Epstein-Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-κB pathway involving TNF receptor-associated factors
17. Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1)
18. Nucleotide sequence of an mRNA transcribed in latent growth-transforming virus infection that it may encode a membrane protein
19. Epstein-Barr virus latent membrane protein-1 (LMP1) C-terminus activation region 2 (CTAR2) maps to the far C-terminus and requires oligomerization for NF-kB activation
20. Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins
21. A simple procedure to increase efficiency of DEAE-dextran transfection of COS cells
22. The transforming domain alone of the Latent Membrane Protein of Epstein-Barr Virus is toxic to cells when expressed at high levels
23. Induction of bcl-2 expression by the Epstein-Barr-virus latent membrane protein-1 protects infected B-cells from programmed cell death
24. Clonability and tumorigenicity of human epithelial cells expressing the EBV encoded membrane protein LMP1
25. Isolation and sequencing of the Epstein-Barr virus BNLF-1 gene (LMP1) from a Chinese nasopharyngeal carcinoma
26. The Epstein-Barr Virus latent membrane protein 1 (LMP1) mediates activation of NF-kB and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain
27. Signal transduction by the c-Jun N-terminal kinase (JNK)-from inflammation to development
28. The Epstein-Barr virus LMP1 amino acid sequence that engages tumor necrosis factor receptor associated factors is critical for primary B lymphocyte growth transformation
29. The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumour necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-kB
30. The residues between the two transformation effector sites of Epstein-Barr virus latent membrane protein 1 are not critical for B-lymphocyte transformation
31. The 30-base-pair deletion in chinese variants of the Epstein-Barr virus LMP1 gene is not the major effector of functional differences between variant LMP1 genes in human lymphocytes
32. Tumour necrosis factor receptor associated factor 2 is a mediator of NF-kB activation by latent infection membrane protein 1, the Epstein-Barr Virus transforming protein
33. Epstein-Barr virus latent membrane protein 1 is essetial for B-lymphocyte growth transformation
34. The Epstein-Barr virus LMP1 cytoplasmic carboxy terminus is essential for B-lymphocyte transformation: Fibroblast cocultivation complements a critical function within the terminal 155 residues
35. The amino-terminus and membrane-spanning domains of LMP-1 inhibit cell proliferation
36. Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade
37. Epstein-Barr virus latent membrane protein-1 oncogene deletions: Correlations with malignancy in Epstein-Barr virus-associated lymphoproliferative disorders and malignant lymphomas
38. Mutational hot spots within the carboxy terminal region of the LMP1 oncogne of Epstein-Barr virus are frequent in lymphoproliferative disorders
39. Deletions within the LMP1 oncogene of Epstein-Barr virus are clustered in Hodgkin's disease and identical to those observed in nasopharyngeal carcinoma
40. The Epstein-Barr Virus LMP-1 product induces A20 zinc finger protein expression by activating nuclear factor-B
41. Posttranslational processing of the Epstein-Barr virus-encoded p63/LMP protein
42. The latent membrane protein oncoprotein resembles growth factor receptors in the properties of its turnover
43. Transformation by the oncogenic latent membrane protein correlates with its rapid turnover, membrane localization, and cytoskeletal association
44. The NPC derived C15 LMP1 protein confers enhanced activtion of NF-κB and induction of the EGFR in epithelial cells
45. Epstein-Barr virus LMP1 induction of the epidermal growth factor receptor is mediated through a TRAF signaling pathway distinct from NF-κB activation
46. Stimulation of NF-kB-mediated transcription by mutant derivatives of the latent membrane protein of Epstein-Barr virus
47. Processing of the Epstein-Barr virus-encoded latent membrane protein p63/LMR
48. All three domains of the Epstein-Barr virus-encoded Latent membrane protein LMP1 are required for transformation of rat-1 fibroblasts
49. The Epstein-Barr virus transforming protein LMP-1 engages signaling proteins for the tumour necrosis factor receptor family
50. Sequence variation of latent membrane protein-1 of Epstein-Barr virus strains associated with hairy leukoplakia
51. Activation of the small GTPase Cdc42 by the inflammatory cytokines TNFα and IL-1, and by the Epstein-Barr virus transforming protein LMP1
52. Aberrant rel/nfkb genes and activity in human cancer
53. Epstein-Barr virus
54. Activation of a Ras-MAPK-dependent pathway by Epstein-Barr Virus latent membrane protein 1 is essential for cellular transformation
55. Monoclonal antibodies to the latent membrane protein of Epstein-Barr virus reveal heterogeneity of the protein and inducible expression in virus-transformed cells
56. Characterization of LMP1's association with TRAF1, TRAF2 and TRAF3
57. Identification of potential hot spots in the carboxy-terminal part of the Epstein-Barr virus (EBV) BNLF-1 gene in both malignant and benign EBV-associated diseases: High frequency of a 30-bp deletion in Malaysian and Danish peripheral T-cell lymphomas
58. Deletions in the Epstein-Barr virus latent membrane protein-1 oncogene in hodgkin's disease
59. Epstein-Barr virus-transforming protein latent membrane protein 1 activates transcription factor NF-κB through a pathway that includes the NF-κB-inducing kinase and the IκB kinases IKKα and IKKβ
60. Epstein-Barr virus (EBV)-encoded membrane protein LMP1 from a nasopharyngeal carcinoma is non-immunogenic in a murine model system, in contrast to a B cell-derived homologue
61. Epstein-Barr Virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23
62. Epstein-Barr Virus latent infection membrane protein alters the human B-lymphocyte phenotype: Deletion of the amino-terminus abolishes activity
63. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells
64. Expression of the Epstein-Barr virus transforming protein LMP1 causes a rapid and transient stimulation of the Bcl-2 homologue Mcl-1 levels in B-cell lines